News

Off-label treatment with apremilast, an oral medication approved for certain inflammatory conditions, helped prevent new inflammatory blisters in an older woman with epidermolysis bullosa acquisita (EBA), a rare autoimmune disease in which blisters form in layers of the skin in response to injury. The 69-year-old woman, who had…

An interview study found that epidermolysis bullosa (EB) can affect nearly every part of children’s daily lives. The children described constant pain and wound care, fear of new wounds, emotional strain, social isolation, and difficulty taking part in normal childhood activities. “Pediatric nurses should provide holistic and child-centered care…

Tiny packets of cellular cargo called extracellular vesicles (EVs) that are released from placental cells may help calm the chronic inflammation that drives scarring and tissue damage in people with recessive dystrophic epidermolysis bullosa (RDEB), a new study found. In laboratory experiments, these extracellular vesicles shifted inflammatory immune cells…

A cell-based study found that a group of experimental drugs designed to restore missing protein production in junctional epidermolysis bullosa (JEB) showed different responses to specific mutations in the COL17A1 gene, a finding researchers said could be used to work toward tailored treatment approaches. The researchers also identified a…

Zevaskyn (prademagene zamikeracel), a gene therapy approved in the U.S. last year to treat the fragile skin disease recessive dystrophic epidermolysis bullosa (RDEB), can now be administered at University of Florida Health, a university-affiliated clinic in Gainesville. That’s according to Abeona Therapeutics, the company that markets Zevaskyn, which…

Children with severe epidermolysis bullosa (EB) who take fiber or iron supplements are likely to take laxatives as well,  a retrospective study in the U.K. found. “Total fibre intake did not reduce the reliance on laxatives or improve stool consistency and frequency in children and adolescents with EB,” the…

Inmune Bio plans to submit regulatory applications in the U.K., U.S., and European Union seeking approval of Ebstrocel, its experimental stem cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company expects to file its application in the U.K. before the end of this year, followed by…

Caring for a child with epidermolysis bullosa (EB) is often logistically challenging, socially fraught, and emotionally exhausting, a new Spanish study underscores. Based on the findings, researchers are calling for more proactive support to be given to families affected by EB. “The findings highlight the need for a more…

Children with recessive dystrophic epidermolysis bullosa (RDEB) and their parents reported less pain and itch, better wound healing, and greater participation in daily activities after treatment with Inmune Bio’s Ebstrocel, an experimental stem cell therapy, during the MissionEB trial, according to a new analysis. The findings build on…

Inmune Bio has assembled a scientific advisory board to help guide its development of Ebstrocel, a stem cell therapy designed to promote wound healing in people with the fragile skin disease RDEB, fully recessive dystrophic epidermolysis bullosa. The newly formed advisory board will provide Inmune with advice ranging…

A U.S.-based biotech company announced that it has reached a “significant” milestone in advancing its experimental stem cell treatment for recessive dystrophic epidermolysis bullosa (RDEB), a rare condition marked by extremely fragile skin. Inmune Bio said it has readied its process for commercial-grade manufacturing of CORDStrom, the stem…

A new biotechnology company called Rinascera Therapeutics has launched to develop therapies for people with epidermolysis bullosa and other rare genetic skin diseases. The company is working to advance two treatment candidates. RIN-002 is being developed for dystrophic epidermolysis bullosa (DEB), while RIN-001 is being developed for another…